# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K
Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 09, 2011

# AXOGEN, INC.

(Exact name of registrant as specified in its charter)

Minnesota	0-16159	41-1301878
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number	Identification No.

13859 Progress Boulevard, Suite 100, Alachua, Florida (Address of Principal Executive Offices)

32615 (Zip Code)

Registrant's telephone number, including area code

(386) 462-6800

 $(Former\ name\ or\ former\ address\ if\ changed\ since\ last\ report,)$ 

ck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 2.02 Results of Operations and Financial Condition

On November 9, 2011, AxoGen, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2011. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1 hereto, shall not be considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

#### Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit

No. Description

99.1 AxoGen, Inc. press release, dated November 9, 2011.

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AXOGEN, INC.

By: /s/ Gregory G. Freitag

Gregory G. Freitag Chief Financial Officer

### EXHIBIT INDEX

Exhibit No.

No. Description

99.1 AxoGen, Inc. press release, dated November 9, 2011.



### **AxoGen Reports Third Quarter 2011 Results**

#### Third Quarter Highlights

- Revenues were \$1.1 million compared to \$0.8 million reported during the third quarter of 2010, an increase of 42.5%
- Revenues were \$3.5 million for nine months compared to \$2.2 million reported for nine months 2010, an increase of 58.8%
- Cash and cash equivalents as of the end of the third quarter was \$10.5 million
- Merger of LecTec Corporation and AxoGen Corporation completed and sales and marketing activity expanding

**ALACHUA, FL – November 9, 2011** – AxoGen, Inc. (OTCBB: AXGN) today reported third quarter of 2011 revenues of \$1.1 million, a 42.5% increase over \$0.8 million reported during the third quarter of 2010. The higher revenues reflect increased penetration into targeted accounts resulting from the broadening of the Company's sales and marketing efforts.

In addition, the Company reported a net loss of \$3.1 million, or \$2.60 per common share, compared to a net loss of \$0.9 million, or \$1.05 per common share, reported during the same period in 2010. The pro forma net loss for the quarter as if the merger had taken place on the first day of the period, was \$3.0 million, or \$0.28 per diluted share, compared to a pro forma net loss of \$1.7 million, or \$0.15 per diluted share, reported during the same period in 2010.

The reported loss for the period included approximately \$643,000 of merger related expenses and \$828,000 associated with a one-time, inventory write-off. These items represent \$1.11 of the \$2.60 loss per common share and \$0.13 of the \$0.28 pro forma loss per common share

"I am pleased with our level of execution during this quarter," stated Karen Zaderej, Chief Executive Officer of AxoGen. "We delivered solid year-over-year, topline growth during a period in which our management team was focused on efforts to complete our merger with LecTec."

#### **Gross Profit**

Gross profit was \$10,436 during the period and \$1.59 million for the nine months and includes an \$828,000 charge related to write-offs associated with expiring inventory and obsolete raw materials. The decrease in gross profit was primarily due to the inventory write-offs with additional contributing factors including a change in product mix and the resumption of manufacturing of Avance® Nerve Graft in January 2011.

#### Sales General and Administrative Expenses (SG&A)

Sales, general and administrative expenses (SG&A) increased to \$2.0 million during the third quarter of 2011, compared to \$1.1 million reported last year and is attributed to the company's strategic and continued broadening of sales and marketing efforts and approximately \$643,000 of merger related expenses.

Ms. Zaderej further commented, "While we are pleased with our topline performance, our merger related efforts impeded sequential growth. With the merger behind us we are now well capitalized and positioned to focus on the execution of our commercialization plan as we move into the fourth quarter."

#### **Financial Liquidity**

At September 30, 2011 the Company had \$10.5 million in cash and cash equivalents and \$4.8 million in long-term debt.

#### Merger Accounting

For accounting purposes, AxoGen Corporation was identified as the acquiring entity and AxoGen, Inc. (formerly "LecTec") as the acquired entity. Accordingly, the condensed consolidated financial statements and related footnote disclosures presented for the period prior to the merger are those of AxoGen Corporation alone. The consolidated financial statements as of September 30, 2011 and December 31, 2010 and for the three months and nine months ended September 30, 2011 and 2010 include the operations and cash flows of AxoGen Corporation through September 30, 2011 and the combined operations and cash flows of AxoGen Corporation and AxoGen, Inc. ("LecTec") subsequent to the merger. The Consolidated Balance Sheet as of September 30, 2011 includes both companies as of such date.

#### **Earnings Call Information**

As previously announced, AxoGen, Inc management will review its third quarter 2011 financials during a conference call scheduled for November 10, 2011 at 3:00 PM Eastern Time. The conference call information is as follows:

Conference dial-in: 888.455.2265
International dial-in 719.457.2605
Conference ID: 3836184

Webcast: www.axogeninc.com/investors.html

An audio replay of the conference call will be available from 6:00 p.m. ET on November 10, 2011, through 6:00 p.m. ET on November 17, 2011 by dialing 888.203.1112 from the U.S. or 719.457.0820 from abroad. The audio webcast will also be available on the company's website, www.axogeninc.com, for one year.

#### About AxoGen, Inc.

AxoGen (OTCBB: AXGN) is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes Avance® Nerve Graft, which AxoGen believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed). AxoGen's portfolio also includes AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector that protects nerves during the body's healing process after surgery. AxoGen is bringing the science of nerve repair to life with over 6,000 surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.

AxoGen (formerly known as LecTec Corporation) is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen's principal executive office and operations are located in Alachua, FL.

#### **Cautionary Statements Concerning Forward-Looking Statements**

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "may", "should", variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-

looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

#### **Contact:**

COCKRELL GROUP
Rich Cockrell, President
404.942.3369
Investorrelations@thecockrellgroup.com
cockrellgroup.com
@COCKRELLGROUP on Twitter

AxoGen, Inc. Greg Freitag, Chief Financial Officer 386.462.6856 InvestorRelations@AxoGenInc.com

Page 4

# AxoGen, Inc. Condensed Consolidated Statements of Operations (unaudited)

	Three Months Ended		Nine Months Ended	
	September 30, 2011	September 30, 2010	September 30, 2011	September 30, 2010 (As Restated)
Revenues	\$ 1,140,768	\$ 800,743	\$ 3,487,824	\$ 2,195,812
Cost of goods sold	1,130,332	160,772	1,893,412	536,185
Gross profit	10,436	639,971	1,594,412	1,659,627
Costs and expenses:				
Sales and marketing	499,118	320,850	1,318,007	975,839
Research and development	76,982	36,169	117,149	75,452
Salaries, wages and related costs	1,189,289	771,518	2,941,530	2,522,419
General and administrative	827,054	336,038	2,005,740	910,585
Depreciation and amortization	44,427	54,220	191,589	208,502
Total costs and expenses	2,636,870	1,518,795	6,574,015	4,692,797
Loss from operations	(2,626,434)	(878,824)	(4,979,603)	(3,033,170)
Other income (expense):				
Interest expense	(318,110)	(193,251)	(954,360)	(516,266)
Interest expense—deferred financing costs	(169,007)	(10,473)	(1,200,413)	(134,808)
Gain from termination of distribution agreement	_	_	_	1,119,094
Change in fair value of warrant liability	_	139,157	62,305	77,695
Other income (expense)	381	28	(10,163)	36
Total other income (expense)	(486,736)	(64,539)	(2,102,631)	390,361
Net loss	\$(3,113,170)	\$ (943,363)	\$(7,082,234)	\$(2,642,809)
Preferred stock dividends	\$ (329,832)	\$ (308,944)	<u>\$(1,028,351</u> )	\$(3,886,801)
Net loss available to common shareholders	\$(3,443,002)	\$(1,252,307)	<u>\$(8,110,585)</u>	\$(3,886,801)
Weighted Average Common Shares outstanding - basic and diluted	1,324,967	1,191,000	1,248,798	715,198
Loss Per Common share - basic and diluted	\$ (2.60)	\$ (1.05)	\$ (6.49)	\$ (5.43)

# AxoGen, Inc. Condensed Consolidated Balance Sheets

Current assets:   Cash and cash equivalents   \$10,525,537   \$1,799,048     Accounts receivable   \$38,109   407,2369     Inventory   1662,343   1902,789     Prepaid expenses   151,846   66,437     Deferred financing costs   151,846   66,437     Deferred financing costs   130,603,03   52,592,524     Property and equipment, net   293,681   500,742     Goodwill   169,877   169,870     Intangible assets   906,566   637,771     Other assets   8,000   8,000     Conditional Stockholders' Equity (Deficit)		September 30, 2011	December 31, 2010
Current assets         Cash and eash equivalents         \$10,525,537         \$1,799,048           Accounts receivable         538,109         407,350           Inventory         1,662,343         1,902,789           Prepaid expenses         181,846         66,437           Deferred financing costs         13,062,803         5,592,54           Property and equipment, net         180,987         -0           Godwill         160,987         -           Other asses         90,696         637,717           Other asses         8,000         8,000           Claritides and Stockholders' Equity (Deficit)         8,000         8,000           Extract liabilities         9,155,711         9,688,18           Current portion of long-term debt         -         1,338,455           Current portion of long-term debt, related party         -         1,338,455           Current portion of long-term debt         -         -         7,080,212           Total current liabilities         1,657,113         9,388,683           Long-term debt         -         -         1,657,113         9,388,683           Long-term debt         -         -         2,659,815           Verrent liabilities         -         -	Assets	(unaudited)	
Cash and cash equivalents         \$10,525,537         \$1,799,048           Accounts receivable         538,109         407,350           Inventory         1,662,343         1,902,789           Prepaid expenses         151,846         66,437           Deferred financing costs         13,062,830         5,259,254           Property and equipment, net         293,681         500,742           Goodwill         169,987         —           Intangible assets         906,960         637,771           Other assets         8,000         8,000           Liabilities         8,000         8,000           Current sortion of long-term debt         —         1,338,455           Current portion of long-term debt, related party         —         1,338,455           Current portion of long-term debt         —         7,080,512           Total current liabilities         1,657,113         9,366,683           Long-term debt         —         1,538,455           Current portion of long-term debt, related party         —         1,538,455           Current portion of long-term debt, related party         —         6,048,378           Long-term debt         —         6,048,378           Warrant liabilities         —			
Accounts receivable   58,100   407,350   10,000000000000000000000000000000000		\$ 10 525 537	\$ 1799.048
Inventory	•	. , ,	. , ,
Prepaid expenses         151,846         66,437           Deferred financing costs         184,959         1,083,030           Tofal current assets         13,062,830         5,259,254           Property and equipment, net         293,681         500,742           Godwill         169,987         −           Itanagile assets         906,960         637,771           Other assets         8,000         8,000           Labilities and Stockholders' Equity (Deficit)         1,444,458         5,645,767           Current Isabilities         1,657,113         9,678,96           Current portion of long-term debt, related party         −         1,338,455           Current portion of long-term debt and accrued expenses         1,657,113         9,688,62           Current portion of long-term debt and term debt and accrued expenses         1,657,113         9,386,83           Long-term debt         4,826,264         −           Prefered stock dividends payable         6,648,378         −           Warrant liabilities         6,648,378         −           Romitments and contingencies         −         4,626,641         −           Series B convertible preferred stock, 5,00001 par value; 17,065,217 shares authorized; 0 and 11,072,239 shares issued and outstanding         −         4,2		,	
Deferred financing costs         184,95         1,083,630           Total current assets         13,062,830         5,259,254           Property and equipment, net         293,681         50,742           Goodwill         169,987         −           Intangible assets         906,960         637,771           Other assets         8,000         8,000           Liabilities and Stockholders' Equity (Deficit)         −           Current liabilities           Accounts payable and accrued expenses         \$1,657,113         \$96,789           Current portion of long-term debt, related party         −         \$1,338,455           Current portion of long-term debt         −         \$1,657,113         \$96,896           Long-term debt         −         \$1,657,113         \$98,686           Long-term debt         −         \$1,657,113         \$98,686           Long-term debt         4,826,264         −         −           Preferred stock dividends payable         4,826,264         −         −           Preferred stock dividends payable         −         6,048,378         −           Warrent liabilities         4,826,264         −         −           Preferred stock dividends payable         −         + </td <td><b>J</b></td> <td></td> <td></td>	<b>J</b>		
Property and equipment, net         293,681         500,742           Good will         169,987         —           Intangible assets         906,960         637,771           Other assets         8,000         8,000           Liabilities and Stockholders' Equity (Deficit)         54,444,458         \$6,405,767           Current liabilities           Accounts payable and accrued expenses         \$1,657,113         \$967,896           Current portion of long-term debt, related party         \$1,657,113         \$938,808           Current portion of long-term debt         \$1,657,113         \$938,808           English         \$4,826,264         \$1,657,113         \$938,808           Preferred stock dividends payable         \$4,826,264         \$1,657,113         \$938,808           Bongterm thisbuilties         \$4,833,73         \$18,105,005         \$1,810,005         \$1,810,005           Commitments and contingeries           Series B convertible preferred stock, \$0,00001 par value; \$1,005,217 shares authorized; 0 and 3,156,259 shares issued and out		184,995	1,083,630
Property and equipment, net         293,681         500,742           Good will         169,987         −           Intangible assets         906,960         637,771           Other assets         8,000         8,000           Liabilities and Stockholders' Equity (Deficit)         51,4441,458         \$ 6,405,767           Current liabilities           Accounts payable and accrued expenses         1,657,113         967,896           Current portion of long-term debt, related party         −         1,338,455           Current portion of long-term debt         −         1,657,113         9,808,603           Long-term debt         −         −         7,080,512           Total current liabilities         4,826,264         −           Preferred stock dividends payable         −         6,043,378         18,105,005           Romitiments and contingencies         Total liabilities         6,483,371         18,105,005           Temporary equity:         Series B convertible preferred stock, \$,00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding         −         4,243,948           Series D convertible preferred stock, \$,00001 par value; 6,799,924 shares authorized; 0 and 30,156,259 shares issued and outstanding         −         8,092,568           Series C convertible	Total current assets	13.062.830	5,259,254
Intangible assets         906,960         637,771           Other assets         8,000         8,000           Liabilities and Stockholders' Equity (Deficit)         5,404,576           Current liabilities           Accounts payable and accrued expenses         \$ 1,657,113         \$ 967,896           Current portion of long-term debt, related party         — 1,338,455         — 2,080,512           Current portion of long-term debt         — 6,048,738         — 7,080,512           Total current liabilities         — 6,048,378         — 7,080,512           Long-term debt         — 4,826,264         — 6           Preferred stock dividends payable         — 7,080,512         — 7,080,512           Acronal liabilities         — 6,048,378         — 7,080,512           Committed and contingencies           Total liabilities         — 6,048,378         — 7,060,915           Series B convertible preferred stock, \$,00001 par value; 17,065,217 shares authorized; 0 and \$,782,009 shares issued and outstanding         — 2,669,815         — 2,669,815           Series D convertible preferred stock, \$,00001 par value; 17,989,24 shares authorized; 0 and \$,782,009 shares issued and outstanding         — 2,699,248         — 2,43,948           Series D convertible preferred stock, \$,00001 par value; 16,798,924 shares authorized; 0 and \$,782,209 shares issued	Property and equipment, net	, ,	· · · · ·
Intangible assets         906,900         637,771           Other assets         8,000         8,000           Labilities and Stockholders' Equity (Deficit)         5,444,145.88         6,405,705           Current labilities           Current portion of long-term debt, related party         1,657,113         967,896           Current portion of long-term debt         1,657,113         938,803           Current portion of long-term debt         1,657,13         938,803           Current portion of long-term debt         1,657,13         938,803           Current debt         4,826,26         −           Total current liabilities         4,826,26         −           Current botk dividends payable         −         6,048,378           Many Libilities         −         6,048,378           Warrent liabilities         −         6,048,378           Chaptered stock dividends payable         −         6,048,378           Warrent liabilities         −         6,048,378           Chaptered stock dividends payable         −         4,269,818           Series B convertible preferred stock, \$,00001 par value; 17,065,217 shares authorized; 0 and \$,250,000         −         4,243,948           Series B convertible preferred stock, \$,00001 par value; 6,709,000 shar	Goodwill	,	<del></del>
Other assets         8.00         8.00           Liabilities and Stockholders' Equity (Deficit)           Current liabilities           Current protion of long-term debt, related parry         \$ 1,657,113         \$ 967,896           Current portion of long-term debt, related parry         — 9.080,512         — 7.080,512           Total current portion of long-term debt         4,820,624         — 9.080,512           Total current portion of long-term debt         4,820,624         — 9.080,512           Total current portion of long-term debt         4,820,624         — 9.080,512           Total current portion of long-term debt         4,820,624         — 9.080,512           Total current portion of long-term debt         4,820,624         — 9.080,512           Total current portion of long-term debt         — 9.080,512         — 9.080,512         — 9.080,512           Total liabilities         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082,502         — 9.082	Intangible assets	· ·	637 771
Stabilities and Stockholders' Equity (Deficit)			· · · · · · · · · · · · · · · · · · ·
Current liabilities			
Current liabilities:           Accounts payable and accrued expenses         \$ 1,657,113         \$ 967,896           Current portion of long-term debt, related party         —         1,338,455           Current portion of long-term debt         —         7,080,512           Total current liabilities         1,657,113         9,386,863           Long-term debt         4,826,264         —           Preferred stock dividends payable         —         6,048,378           Warrant liability         —         2,669,815           Total liabilities         6,483,377         18,105,056           Commitments and contingencies         —         4,243,948           Series B convertible preferred stock, \$,00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding         —         4,243,948           Series C convertible preferred stock, \$,00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding         —         8,092,568           Series D convertible preferred stock, \$,00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding         —         1,512,000           Stockholders' equity (deficit):         —         10,949,812         12,000           Common stock, \$,01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,	Liabilities and Stockholders' Equity (Deficit)	Ψ 11,111,150	φ 0,103,707
Accounts payable and accrued expenses         \$1,657,113         \$967,896           Current portion of long-term debt, related party         —         1,338,455           Current portion of long-term debt         —         7,080,512           Total current liabilities         1,657,113         9,386,863           Long-term debt         4,826,264         —           Preferred stock dividends payable         —         6,048,378           Warrant liabilities         —         6,483,377         18,105,056           Commitments and contingencies         —         2,669,815           Temporary equity:         —         4,243,948           Series B convertible preferred stock, \$.00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding         —         4,243,948           Series C convertible preferred stock, \$.00001 par value; 16,798,924 shares authorized; 0 and 30,156,259 shares issued and outstanding         —         3,075,523           Series D convertible preferred stock, \$.00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding         —         3,075,523           Total temporary equity         —         15,412,039           Stockholders' equity (deficit):         109,498         12,056           Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outs	Liabilities and Stockholders Equity (Deficit)		
Current portion of long-term debt, related party         —         1,338,455           Current portion of long-term debt         —         7,080,512           Total current liabilities         1,657,113         9,386,863           Long-term debt         4,826,264         —         6,048,378           Warrant liability         —         6,698,155           Total liabilities         6,483,377         18,105,056           Commitments and contingencies           Temporary equity:           Series B convertible preferred stock, \$,00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding         —         4,243,948           Series C convertible preferred stock, \$,00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding         —         8,092,568           Series D convertible preferred stock, \$,00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding         —         3,075,523           Total temporary equity         —         15,412,039           Stockholders' equity (deficit):         109,498         12,056           Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$,00001 par value; 2,544,750         —         1,125,000           Additional paid-in capital         54,14	Current liabilities:		
Current portion of long-term debt         7,080,512           Total current liabilities         1,657,113         9,386,863           Long-term debt         4,826,264         —           Preferred stock dividends payable         —         6,048,378           Warrant liability         —         2,669,815           Total liabilities         6,483,377         18,105,056           Commitments and contingencies           Temporary equity:           Series B convertible preferred stock, \$,00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding         —         4,243,948           Series C convertible preferred stock, \$,00001 par value; 16,798,924 shares authorized; 0 and 31,1072,239 shares issued and outstanding         —         8,092,568           Series D convertible preferred stock, \$,00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding         —         3,075,523           Total temporary equity         —         15,412,039           Stockholders' equity (deficit):         109,498         12,056           Common stock, \$,01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$,00001 par value; 2,544,750         —         —         1,125,000           Additional paid-in capital         54,142,532         9,934,980		\$ 1,657,113	\$ 967,896
Total current liabilities         1,657,113         9,386,863           Long-term debt         4,826,264         —           Preferred stock dividends payable         —         6,048,378           Warrant liability         —         2,669,815           Total liabilities         6,483,377         18,105,056           Commitments and contingencies           Temporary equity:           Series B convertible preferred stock, \$,00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding         —         4,243,948           Series C convertible preferred stock, \$,00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding         —         8,092,568           Series D convertible preferred stock, \$,00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding         —         3,075,523           Total temporary equity         —         15,412,039           Stockholders' equity (deficit):         109,498         12,056           Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750         —         1,125,000           Additional paid-in capital         54,142,532         9,934,980           Accumulated deficit         (46,293,949)         (38,183,364)		_	1,338,455
Long-term debt         4,826,264         —           Preferred stock dividends payable         —         6,048,378           Warrant liability         —         2,669,815           Total liabilities         6,483,377         18,105,056           Commitments and contingencies           Temporary equity:           Series B convertible preferred stock, \$.00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding         —         4,243,948           Series C convertible preferred stock, \$.00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding         —         8,092,568           Series D convertible preferred stock, \$.00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding         —         3,075,523           Total temporary equity         —         15,412,039           Stockholders' equity (deficit):         109,498         12,056           Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750         —         1,125,000           Additional paid-in capital         54,142,532         9,934,980           Accumulated deficit         (46,293,949)         (38,183,364)           Total stockholders' equity (deficit)         7,958,081         (27,111,	Current portion of long-term debt		7,080,512
Preferred stock dividends payable         —         6,048,378           Warrant liability         —         2,669,815           Total liabilities         6,483,377         18,105,056           Commitments and contingencies           Temporary equity:           Series B convertible preferred stock, \$,00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding         —         4,243,948           Series C convertible preferred stock, \$,00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding         —         8,092,568           Series D convertible preferred stock, \$,00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding         —         3,075,523           Total temporary equity         —         15,412,039           Stockholders' equity (deficit):         109,498         12,056           Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$,00001 par value; 2,544,750         —         1,125,000           Additional paid-in capital         54,142,532         9,934,980           Accumulated deficit         (46,293,949)         (38,183,364)           Total stockholders' equity (deficit)         7,958,081         (27,111,328)	Total current liabilities	1,657,113	9,386,863
Warrant liability	Long-term debt	4,826,264	
Total liabilities         6,483,377         18,105,056           Commitments and contingencies           Temporary equity:           Series B convertible preferred stock, \$.00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding — 4,243,948           Series C convertible preferred stock, \$.00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding — 8,092,568           Series D convertible preferred stock, \$.00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding — 15,412,039           Total temporary equity         — 15,412,039           Stockholders' equity (deficit): 10949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750         109,498         12,056           Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750         — 1,125,000           Additional paid-in capital Accumulated deficit (46,293,949) (38,183,364)         — 3,075,523           Total stockholders' equity (deficit)         7,958,081 (27,111,328)	Preferred stock dividends payable	_	6,048,378
Total liabilities         6,483,377         18,105,056           Commitments and contingencies           Temporary equity:           Series B convertible preferred stock, \$.00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding — 4,243,948           Series C convertible preferred stock, \$.00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding — 8,092,568           Series D convertible preferred stock, \$.00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding — 15,412,039           Total temporary equity         — 15,412,039           Stockholders' equity (deficit):         109,498         12,056           Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750         — 1,125,000           Additional paid-in capital Accumulated deficit (46,293,949)         54,142,532         9,934,980           Accumulated deficit (46,293,949)         (38,183,364)           Total stockholders' equity (deficit)         7,958,081         (27,111,328)	Warrant liability		2,669,815
Commitments and contingencies           Temporary equity:           Series B convertible preferred stock, \$.00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding	Total liabilities	6 483 377	
Temporary equity:  Series B convertible preferred stock, \$.00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding — 4,243,948  Series C convertible preferred stock, \$.00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding — 8,092,568  Series D convertible preferred stock, \$.00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding — 3,075,523  Total temporary equity — 15,412,039  Stockholders' equity (deficit): 109,498 12,056  Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750 shares authorized, issued and outstanding — 1,125,000  Additional paid-in capital 54,142,532 9,934,980  Accumulated deficit (46,293,949) (38,183,364)  Total stockholders' equity (deficit) 7,958,081 (27,111,328)	Commitments and contingencies	0,103,377	
Series B convertible preferred stock, \$.00001 par value; 17,065,217 shares authorized; 0 and 9,782,609 shares issued and outstanding — 4,243,948  Series C convertible preferred stock, \$.00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding — 8,092,568  Series D convertible preferred stock, \$.00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding — 3,075,523  Total temporary equity — 15,412,039  Stockholders' equity (deficit): 109,498 1 2,056  Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750 shares authorized, issued and outstanding Mdditional paid-in capital 54,142,532 9,934,980  Accumulated deficit (46,293,949) (38,183,364)  Total stockholders' equity (deficit) 7,958,081 (27,111,328)	_		
9,782,609 shares issued and outstanding — 4,243,948 Series C convertible preferred stock, \$.00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding — 8,092,568 Series D convertible preferred stock, \$.00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding — 3,075,523  Total temporary equity — 15,412,039 Stockholders' equity (deficit): 109,498 12 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750 shares authorized, issued and outstanding Meditional paid-in capital 54,142,532 9,934,980 Accumulated deficit (46,293,949) (38,183,364) Total stockholders' equity (deficit) 7,958,081 (27,111,328)			
Series C convertible preferred stock, \$.00001 par value; 16,798,924 shares authorized; 0 and 11,072,239 shares issued and outstanding — 8,092,568 Series D convertible preferred stock, \$.00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding — 3,075,523  Total temporary equity — 15,412,039  Stockholders' equity (deficit): 109,498 12,056  Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750 shares authorized, issued and outstanding — 1,125,000  Additional paid-in capital 54,142,532 9,934,980  Accumulated deficit (46,293,949) (38,183,364)  Total stockholders' equity (deficit) 7,958,081 (27,111,328)			4 243 948
11,072,239 shares issued and outstanding       —       8,092,568         Series D convertible preferred stock, \$.00001 par value; 67,000,000 shares authorized; 0 and 30,156,259 shares issued and outstanding       —       3,075,523         Total temporary equity       —       15,412,039         Stockholders' equity (deficit):       109,498       12,056         Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750       —       1,125,000         Additional paid-in capital       54,142,532       9,934,980         Accumulated deficit       (46,293,949)       (38,183,364)         Total stockholders' equity (deficit)       7,958,081       (27,111,328)			.,2 .5,5 .6
30,156,259 shares issued and outstanding       —       3,075,523         Total temporary equity       —       15,412,039         Stockholders' equity (deficit):       109,498       12,056         Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750       —       1,125,000         Additional paid-in capital       54,142,532       9,934,980         Accumulated deficit       (46,293,949)       (38,183,364)         Total stockholders' equity (deficit)       7,958,081       (27,111,328)		_	8,092,568
Total temporary equity         —         15,412,039           Stockholders' equity (deficit):         109,498         12,056           Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750         —         1,125,000           Additional paid-in capital         54,142,532         9,934,980           Accumulated deficit         (46,293,949)         (38,183,364)           Total stockholders' equity (deficit)         7,958,081         (27,111,328)			
Stockholders' equity (deficit):         109,498         12,056           Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750         —         1,125,000           Additional paid-in capital         54,142,532         9,934,980           Accumulated deficit         (46,293,949)         (38,183,364)           Total stockholders' equity (deficit)         7,958,081         (27,111,328)	30,156,259 shares issued and outstanding		3,075,523
Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750 shares authorized, issued and outstanding  Additional paid-in capital  Accumulated deficit  Total stockholders' equity (deficit)  Total stockholders' equity (deficit)  1,125,000  54,142,532 9,934,980  (46,293,949) (38,183,364) 7,958,081 (27,111,328)	Total temporary equity		15,412,039
Common stock, \$.01 par value; 50,000,000 shares authorized; 10,949,812 and 1,205,624 shares issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750 shares authorized, issued and outstanding  Additional paid-in capital  Accumulated deficit  Total stockholders' equity (deficit)  Total stockholders' equity (deficit)  Total stockholders' equity (deficit)  Common stock, \$.01 par value; 20,949,812 and 1,205,624 shares authorized; 1,205,000	Stockholders' equity (deficit):	109,498	12,056
issued and outstanding Series A convertible preferred stock, \$.00001 par value; 2,544,750 shares authorized, issued and outstanding  Additional paid-in capital  Accumulated deficit  Total stockholders' equity (deficit)  - 1,125,000 - 1,125,000 - 4,142,532 - 9,934,980 - (46,293,949) - (38,183,364) - (27,111,328)		,	,
shares authorized, issued and outstanding       —       1,125,000         Additional paid-in capital       54,142,532       9,934,980         Accumulated deficit       (46,293,949)       (38,183,364)         Total stockholders' equity (deficit)       7,958,081       (27,111,328)			
Accumulated deficit       (46,293,949)       (38,183,364)         Total stockholders' equity (deficit)       7,958,081       (27,111,328)	shares authorized, issued and outstanding	_	
Total stockholders' equity (deficit) 7,958,081 (27,111,328)	Additional paid-in capital	54,142,532	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Accumulated deficit	(46,293,949)	(38,183,364)
<u>\$ 14,441,458</u>	Total stockholders' equity (deficit)	7,958,081	(27,111,328)
		\$ 14,441,458	\$ 6,405,767